Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company focused on cancer therapies. It was incorporated in 2005, is headquartered in Waltham, Massachusetts, and is listed on Nasdaq as SNDX.
Syndax Pharmaceuticals announced a collaboration to expand global access to Revuforj while reporting strong commercial performance for its two marketed products, with Revuforj generating $125 million and Niktimvo $152 million in the first 11 months of sales.
Syndax Pharmaceuticals partnered with World Orphan Drug Alliance to launch a Managed Access Program for Revuforj in multiple regions. A price target was raised to $28 while maintaining a Buy rating.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07563010 |
Menin-Inhibitor Targeted Maintenance in AML |
NOT_YET_RECRUITING | PHASE2 |
| NCT07283640 |
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia |
NOT_YET_RECRUITING | PHASE1 |
| NCT07211958 |
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation |
RECRUITING | PHASE3 |
| NCT06313437 |
Revumenib in Combination With 7+3 + Midostaurin in AML |
RECRUITING | PHASE1 |
| NCT06284486 |
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib |
RECRUITING | PHASE1/PHASE2 |
| NCT06229912 |
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes |
RECRUITING | PHASE2 |
| NCT06226571 |
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias |
RECRUITING | PHASE1 |
| NCT06177067 |
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia |
RECRUITING | PHASE1 |
| NCT06132256 |
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT05918913 |
Expanded Access Program for Revumenib |
NO_LONGER_AVAILABLE |
